Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anidulafungin - Pfizer

Next Previous
X
Search
Drug Profile

Anidulafungin - Pfizer

Alternative Names: Ecalta; ECB; Eraxis; LY303366; PF-3910960; V-echinocandin; VEC; VER 002; VER-02

Latest Information Update: 03 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Pfizer
  • Class Antifungals; Cyclic peptides
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Candidiasis

Highest Development Phases

  • Marketed Candidaemia; Candidiasis
  • Discontinued Invasive bronchopulmonary aspergillosis; Pneumocystis pneumonia

Most Recent Events

  • 03 Jan 2024 No development reported - Phase-III for Candidaemia (In adolescents, In children, In infants) in Brazil, Spain, Portugal, Greece, Italy, Taiwan, Russia, South Korea, Canada, USA (IV) (EudraCT2008-004150-32; NCT00761267)
  • 03 Jan 2024 No development reported - Phase-III for Candidiasis (In adolescents, In children, In infants) in Spain, Portugal, Greece, Italy, Taiwan, Russia, South Korea, Canada, USA, Brazil (IV) (EudraCT2008-004150-32; NCT00761267)
  • 08 Apr 2021 Discontinued - Phase-III for Invasive bronchopulmonary aspergillosis (Combination therapy) in Australia (IV) (NCT00531479)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top